{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:58:18Z","timestamp":1779209898830,"version":"3.51.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.32262","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T16:01:08Z","timestamp":1636646468000},"page":"e2132262","source":"Crossref","is-referenced-by-count":9,"title":["Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of<i>BRAF V600<\/i>Variation Metastatic Melanoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Chao","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, Florida"},{"name":"Department of Immunology, Moffitt Cancer Center & Research Institute, Tampa, Florida"},{"name":"Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"zoi210920r1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","article-title":"Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma.","volume":"10","author":"Yu","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"zoi210920r2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-011-1079-2","article-title":"Combination of targeted therapy and immunotherapy in melanoma.","volume":"60","author":"Blank","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"zoi210920r3","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.2147\/OTT","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"7","key":"zoi210920r4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/imt-2018-0208","article-title":"Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.","volume":"11","author":"Atkins","year":"2019","journal-title":"Immunotherapy"},{"key":"zoi210920r5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma.","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"key":"zoi210920r6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT","article-title":"Melanoma treatment in review.","volume":"7","author":"Domingues","year":"2018","journal-title":"Immunotargets Ther"},{"issue":"23","key":"zoi210920r7","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","article-title":"Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.","volume":"71","author":"Villanueva","year":"2011","journal-title":"Cancer Res"},{"issue":"10240","key":"zoi210920r8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"zoi210920r9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"zoi210920r11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"zoi210920r12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.chb.2015.09.008","article-title":"Comparative evaluation of the reliability and validity of three data extraction programs: UnGraph, GraphClick, and DigitizeIt.","volume":"55","author":"Rakap","year":"2016","journal-title":"Computers in Human Behavior"},{"issue":"6","key":"zoi210920r13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"issue":"3","key":"zoi210920r14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","article-title":"Survival extrapolation in cancer immunotherapy: a validation-based case study.","volume":"22","author":"Bullement","year":"2019","journal-title":"Value Health"},{"issue":"4","key":"zoi210920r15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","article-title":"Accounting for cured patients in cost-effectiveness analysis.","volume":"20","author":"Othus","year":"2017","journal-title":"Value Health"},{"issue":"12","key":"zoi210920r16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia.","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"2","key":"zoi210920r17","doi-asserted-by":"publisher","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma.","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi210920r18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/CEOR","article-title":"Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.","volume":"10","author":"Gibson","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"12","key":"zoi210920r19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"zoi210920r20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107255","article-title":"Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.","volume":"9","author":"Curl","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"zoi210920r21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/imt-2018-0168","article-title":"Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.","volume":"11","author":"Tarhini","year":"2019","journal-title":"Immunotherapy"},{"issue":"11","key":"zoi210920r22","first-page":"1227","article-title":"Budget impact of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E\/K mutation-positive melanoma from a US commercial payer perspective.","volume":"25","author":"Stellato","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"zoi210920r23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer.","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"zoi210920r24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3111\/13696998.2012.739226","article-title":"Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.","volume":"16","author":"Barzey","year":"2013","journal-title":"J Med Econ"},{"issue":"2","key":"zoi210920r25","first-page":"158","article-title":"Economic burden associated with adverse events in patients with metastatic melanoma.","volume":"21","author":"Arondekar","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"zoi210920r26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi210920r27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jama.2019.1153","article-title":"Choosing a time horizon in cost and cost-effectiveness analyses.","volume":"321","author":"Basu","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"zoi210920r28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","article-title":"The influence of time horizon on results of cost-effectiveness analyses.","volume":"17","author":"Kim","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"zoi210920r29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20141.","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"26","key":"zoi210920r30","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi210920r31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/00019053-200826090-00005","article-title":"Estimating \u2018costs\u2019 for cost-effectiveness analysis.","volume":"26","author":"Miners","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"zoi210920r33","doi-asserted-by":"publisher","first-page":"e1911952","DOI":"10.1001\/jamanetworkopen.2019.11952","article-title":"Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non\u2013small cell lung cancer in the United States.","volume":"2","author":"Criss","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi210920r34","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma.","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi210920r35","doi-asserted-by":"publisher","first-page":"e214846","DOI":"10.1001\/jamanetworkopen.2021.4846","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma.","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi210920r38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2019.07.003","article-title":"Economic evaluation of systemic treatments for advanced melanoma: a systematic review.","volume":"23","author":"Gorry","year":"2020","journal-title":"Value Health"},{"key":"zoi210920r32","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"zoi210920r36","volume-title":"Making Medicines Affordable: A National Imperative","author":"National Academies of Sciences, Engineering, and Medicine","year":"2018"},{"key":"zoi210920r10","unstructured":"Rohatgi? A. WebPlotDigitizer. Accessed October 12, 2021. https:\/\/automeris.io\/WebPlotDigitizer\/"},{"key":"zoi210920r37","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination: cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. Accessed October 12, 2021. https:\/\/www.nice.org.uk\/guidance\/ta414\/documents\/final-appraisal-determination-document"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2785982\/cai_2021_oi_210920_1635866642.99683.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T14:15:50Z","timestamp":1699798550000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2785982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.32262","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]}}}